Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 189857, 8 pages
http://dx.doi.org/10.1155/2015/189857
Clinical Study

Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading

1Departamento de Ciencias de Salud, Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, Calle 21 Sur 1103, Barrio de Santiago, 72410 Puebla, Mexico
2Outpatient Diabetes Clinic PEMEX, Calle 46 Poniente 1502, Colonia Cleotilde Torres, 72050 Puebla, Mexico
3Hospital Universitario de Puebla, Benemerita Universidad Autonoma de Puebla, Avenida 25 Poniente 1301, Colonia Los Volcanes, 72410 Puebla, Mexico
4Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany
5Department of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Moorenstraße 5, 40225 Düsseldorf, Germany

Received 9 June 2015; Revised 21 July 2015; Accepted 22 July 2015

Academic Editor: Mark A. Yorek

Copyright © 2015 Hector Garcia-Alcala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. ENSANUT, Encuesta Nacional de Salud y Nutrición, 2012, http://ensanut.insp.mx/resultados_principales.php#.VRv75uEzo8Q.
  2. J. I. E. Guerra, “Estrés oxidativo, enfermedades y tratamientos antioxidantes,” Anales de Medicina Interna, vol. 18, no. 6, pp. 326–335, 2001. View at Publisher · View at Google Scholar
  3. D. Ziegler, N. Papanas, A. I. Vinik, and J. E. Shaw, “Epidemiology of polyneuropathy in diabetes and prediabetes,” Handbook of Clinical Neurology, vol. 126, pp. 3–22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. W. Brownrigg, S. de Lusignan, A. McGovern et al., “Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus,” Heart, vol. 100, pp. 1837–1843, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Calles-Escandón, L. C. Lovato, D. G. Simons-Morton et al., “Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial,” Diabetes Care, vol. 33, no. 4, pp. 721–727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi et al., “Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials,” The British Medical Journal, vol. 343, no. 7817, Article ID d4169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. N. B. Finnerup, N. Attal, S. Haroutounian et al., “Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis,” The Lancet Neurology, vol. 14, no. 2, pp. 162–173, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Ziegler and V. Fonseca, “From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy,” Journal of Diabetes and its Complications, vol. 29, no. 1, pp. 146–156, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Ziegler, S. Buchholz, C. Sohr, J. Nourooz-Zadeh, and M. Roden, “Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients,” Acta Diabetologica, vol. 52, pp. 65–72, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. A. J. M. Boulton, P. Kempler, A. Ametov, and D. Ziegler, “Whither pathogenetic treatments for diabetic polyneuropathy?” Diabetes/Metabolism Research and Reviews, vol. 29, no. 5, pp. 327–333, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Papanas and D. Ziegler, “Efficacy of α-lipoic acid in diabetic neuropathy,” Expert Opinion on Pharmacotherapy, vol. 15, no. 18, pp. 2721–2731, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Ziegler, P. A. Low, W. J. Litchy et al., “Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy. The NATHAN 1 trial,” Diabetes Care, vol. 34, no. 9, pp. 2054–2060, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Ziegler, H. Nowak, P. Kempler, P. Vargha, and P. A. Low, “Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis,” Diabetic Medicine, vol. 21, no. 2, pp. 114–121, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Rutkove and C. E. McIlduff, “Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy,” Therapeutics and Clinical Risk Management, vol. 2011, no. 7, pp. 377–385, 2011. View at Publisher · View at Google Scholar
  16. G. S. Mijnhout, B. J. Kollen, A. Alkhalaf, N. Kleefstra, and H. J. G. Bilo, “Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials,” International Journal of Endocrinology, vol. 2012, Article ID 456279, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. K.-J. Ruhnau, H. P. Meissner, J.-R. Finn et al., “Effects of 3-week oral treatment with the antioxidant thioctic acid (α- lipoic acid) in symptomatic diabetic polyneuropathy,” Diabetic Medicine, vol. 16, no. 12, pp. 1040–1043, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Ziegler, A. Ametov, A. Barinov et al., “Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 Trial,” Diabetes Care, vol. 29, no. 11, pp. 2365–2370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. M. Boulton, D. G. Armstrong, S. F. Albert, and et al, “Comprehensive foot examination and risk assessment. A report of the task force of the foot care interest group of the American diabetes association, with endorsement by the American association of clinical endocrinologists,” Diabetes Care, vol. 31, pp. 1679–1685, 2008. View at Google Scholar
  20. E. L. Feldman, M. J. Stevens, P. K. Thomas, M. B. Brown, N. Canal, and D. A. Greene, “A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy,” Diabetes Care, vol. 17, no. 11, pp. 1281–1289, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. B. S. Galer, A. Gianas, and M. P. Jensen, “Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life,” Diabetes Research and Clinical Practice, vol. 47, no. 2, pp. 123–128, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Daousi, S. J. Benbow, A. Woodward, and I. A. MacFarlane, “The natural history of chronic painful peripheral neuropathy in a community diabetes population,” Diabetic Medicine, vol. 23, no. 9, pp. 1021–1024, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Berger, E. Dukes, J. Edelsberg, B. Stacey, and G. Oster, “Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy,” Clinical Journal of Pain, vol. 23, no. 3, pp. 251–258, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. B. W. C. Bongaerts, W. Rathmann, M. Heier et al., “Older subjects with diabetes and prediabetes are frequently unaware of having distal sensorimotor polyneuropathy: the KORA F4 study,” Diabetes Care, vol. 36, no. 5, pp. 1141–1146, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. A. H. Garcia and G. C. Garcia, “Experience in Mexico with alpha lipoic acid (ALA) for treatment of diabetic neuropathy (DN). Results of a postmarketing survey,” in Proceedings of the 18th Annual Meeting of the Diabetic Neuropathy Study Group of the EASD, Orvieto, Italy, September 2008.
  26. J. Raskin, Y. L. Pritchett, F. Wang et al., “A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain,” Pain Medicine, vol. 6, no. 5, pp. 346–356, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. R. A. Moore, S. Derry, and P. J. Wiffen, “Challenges in design and interpretation of chronic pain trials,” British Journal of Anaesthesia, vol. 111, no. 1, pp. 38–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. S. Gewandter, R. H. Dworkin, D. C. Turk et al., “Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations,” Pain, vol. 155, no. 9, pp. 1683–1695, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Schwartz, M. S. Etropolski, D. Y. Shapiro et al., “A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy,” Clinical Drug Investigation, vol. 35, pp. 95–108, 2015. View at Publisher · View at Google Scholar · View at Scopus